Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
David L. Barker
AddedMar 31, 2024
UpdatedMay 31, 2026
David L. Barker

David L. Barker

Board Member, Bionano Genomics

LinkedIn

David L. Barker's Career

Bionano Genomics
Bionano Genomics

San Diego, CA, US

Board Member· Board
Singular Genomics
Singular Genomics

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

David L. Barker's Career

Bionano Genomics
Bionano Genomics
Public$288.1M4052003San Diego, CA, US
Board Member· Board

Leadership at Bionano Genomics

Tracy WarrenTracy WarrenBoard Member
Kristiina VuoriKristiina VuoriBoard Member
Hannah MamuszkaHannah MamuszkaBoard Member
Han CaoHan CaoFounder
Albert LudererAlbert LudererBoard Member
Christopher TwomeyChristopher TwomeyBoard Member

Similar to Bionano Genomics

Singular GenomicsSingular GenomicsSan Diego, CA, USGenomic Technologiesest. 2016Singular GenomicsSan Diego, CA, US · est. 2016

Singular Genomics: A dynamic, fast-paced biotech company in California, innovating in genomic technologies.

Public · $176M134
10x Genomics10x GenomicsPleasanton, CA, USGene Sequencingest. 201210x GenomicsPleasanton, CA, US · est. 2012

10x Genomics: A leading American biotech firm, innovating in gene sequencing since 2012.

Public · $242.6M448
GenomenonGenomenonAnn Arbor, MI, USData, Softwareest. 2014GenomenonAnn Arbor, MI, US · est. 2014

Genomenon: Comprehensive genomic evidence provider, aiding in critical biomarker identification.

Series B · $32.8M80
Element BiosciencesElement BiosciencesSan Diego, CA, USGenetic Analysis Toolsest. 2017Element BiosciencesSan Diego, CA, US · est. 2017

San Diego-based biotech firm specializing in the development of genetic analysis tools.

Series C · $401M348
Singular Genomics
Singular Genomics
Public$176M1342016San Diego, CA, US
Board Member· Board

Leadership at Singular Genomics

Drew SpaventaDrew SpaventaBoard Member
Eli GlezerEli GlezerBoard Member

Similar to Singular Genomics

10x Genomics10x GenomicsPleasanton, CA, USGene Sequencingest. 201210x GenomicsPleasanton, CA, US · est. 2012

10x Genomics: A leading American biotech firm, innovating in gene sequencing since 2012.

Public · $242.6M448
Spatial GenomicsSpatial GenomicsPasadena, CA, USGenomic Analysisest. 2016Spatial GenomicsPasadena, CA, US · est. 2016

Pioneering spatial analysis and comprehensive single-cell assay in intact cells and tissues.

Series A · $56M24
BioSkryb GenomicsBioSkryb GenomicsDurham, NC, USGenomic Toolsest. 2018BioSkryb GenomicsDurham, NC, US · est. 2018

BioSkryb Genomics: Transforming single cell discovery with advanced genomic tools for disease management.

Series A · $31.5M83

David L. Barker's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailHiroshi MikitaniHiroshi MikitaniBoard Member · RakutenKen KutaragiKen KutaragiBoard Member · RakutenTakashi MitachiTakashi MitachiBoard Member · Rakuten

People Similar to David L. Barker

R Erik HolmlinR Erik HolmlinBoard Member · Bionano GenomicsBill YoungBill YoungBoard Member · Theravance BiopharmaDan KidleDan KidleBoard Member · Jumpcode GenomicsGrace ColónGrace ColónBoard Member · CareDxTroy CoxTroy CoxBoard Member · LetsGetCheckedRonald I DozoretzRonald I DozoretzBoard Member · Genomind